Vanguard Biotech Systems
Bioinformatics infrastructure for traceable antimicrobial resistance analysis.
Vanguard Biotech Systems develops controlled bioinformatics software to organise WGS processing, resistance-related evidence, provenance and reporting into traceable, reviewable outputs.
NextGenAMR is our first product — a functional platform in controlled preview for organising WGS analyses related to antimicrobial resistance.
NextGenAMR is a functional platform in controlled preview. Validation is ongoing, and the product is not presented as an autonomous diagnostic or treatment-decision system.
In plain terms
A bacterial sequence within the supported scope is processed through a controlled workflow. NextGenAMR organises resistance-related signals, preserves the traceability of how they were obtained, and generates structured outputs for a professional to review together with other tests and the relevant context.
- 01Supported input
- 02Controlled workflow
- 03Structured outputs
- 04Professional review
Why we build this
Bioinformatics workflows often combine several components, versions, databases, transformations and hand-offs. That fragmentation makes it hard to keep scope, configuration, provenance, warnings and outputs consistent across the whole process. VBS works on the control, organisation, traceability and reporting layer that turns technical components into a more governed, reviewable process — without replacing the specialists who interpret the results.
Current scope
NextGenAMR works with supported WGS inputs within a defined, versioned scope, and produces structured outputs. The scope is deliberately bounded.
- Operational species
- Escherichia coli
- Antibiotic panel
- 9
- Scope version
- 2026.07.0 · 2026-07-15
The current published operational scope is Escherichia coli, with a closed, species-specific panel of 9 antibiotics. NextGenAMR is species-specific by design and built to expand; additional species are in internal development and are not yet available.
See the full scope on NextGenAMR →How it works, at a high level
- 1 · Controlled intake
A supported WGS input is received and prepared within the defined scope.
- 2 · Processing & AMR evidence
A controlled bioinformatics workflow organises resistance-related evidence.
- 3 · Quality, scope & provenance
Quality gates, scope checks and warnings apply; the system may abstain, and every step keeps its provenance. It is not always a successful call.
- 4 · Reviewable outputs
Structured, traceable outputs are generated for a professional to review together with other tests.
A look at the product
Demonstration generated from real bacterial sample data during internal testing with the current version of NextGenAMR. The content illustrates product outputs and does not by itself constitute a clinical validation result or treatment recommendation.
| Antibiotic | Status | Evidence |
|---|---|---|
| Amoxicillin–clavulanic acid | Probable resistance | blaTEM-1B |
| Ampicillin | Probable resistance | blaTEM-1B |
| Ciprofloxacin | Probable resistance | gyrA S83L · parC S80I |
| Ceftazidime | Probable susceptibility | no ESBL markers |
| Gentamicin | Probable susceptibility | — |
| Meropenem | Probable susceptibility | no carbapenemase |
| Nitrofurantoin | Probable susceptibility | — |
| Piperacillin–tazobactam | Probable susceptibility | — |
| Trimethoprim–sulfamethoxazole | Probable resistance | sul1 · dfrA17 |
- AMR genes7
- Point mutations3
- Plasmid replicons2
- Mean coverage82×
- pipeline · ngamr-core@0.4.2
- db · card-2025.09 · resfinder-2025.10
- operator · lab.ops/41
- started · 2026-06-19 09:14 UTC
- Low-coverage region flagged for review.
- Result reviewed — no out-of-scope call emitted.
What you are looking at
- 01Panels group the organised evidence per antibiotic in the supported panel.
- 02Each result is a calibrated probability, never a categorical S/I/R decision.
- 03Warnings and abstentions are shown where evidence or quality is insufficient.
- 04Run provenance (versions, databases, timing) is preserved and reviewable.
- 05The output is structured for a professional to review — the system does not make an autonomous clinical decision.
Text description: the product view shows, per antibiotic in the supported panel, the organised evidence as a calibrated probability (not S/I/R), with warnings and abstentions where relevant, the run provenance, and a structured output for professional review; the system makes no autonomous clinical decision.
Who it is for
Clinical & microbiology laboratories
Controlled processing within a defined scope, structured outputs, warnings, traceability and professional review — to assess fit with your local workflow. No claims about time-to-treatment or cost.
Assess institutional fit →Research & surveillance
Reproducibility, provenance, versioning and normalised, comparable outputs within the supported scope. Not presented as a national surveillance or epidemiological system.
Explore the product →Institutional, IT, security & leadership
Governance, auditability, version control, evaluable security, controlled deployment and documentation for due diligence.
See security →Status, evidence & validation
NextGenAMR is currently undergoing controlled evaluation and internal, non-clinical validation. Validation results have not been published and must not be inferred.
No clinical performance metrics (sensitivity, specificity, categorical agreement, VME/ME, accuracy) have been published. Performance evaluation is in progress.
See evidence & validation status →Security & assurance
Each run preserves provenance and execution metadata and produces structured, auditable outputs for professional review (JSON and PDF).
- Access controlimplemented
- Run-level provenance & audit trailimplemented
- Environment separation (staging / production)implemented
- Formal compliance certificationsnot claimed
Vanguard Biotech Systems does not currently make regulatory-authorisation or autonomous-clinical-use claims for NextGenAMR. Intended use and regulatory strategy will be assessed as the product evolves.
See security & deployment →About Vanguard Biotech Systems
Vanguard Biotech Systems is a Spanish technology company founded in 2025 and based in Granada, Spain. It develops bioinformatics software infrastructure to turn complex genomic workflows into more controlled, reproducible, traceable and reviewable processes.
Vanguard Biotech Systems' mission is to make complex bioinformatics processes more structured, governed and auditable, while preserving scope, versions, evidence, provenance, system limitations and professional review.
- Founded
- Founded in 2025 in Granada, Spain.
- Location
- Granada, Spain
- Product
- NextGenAMR — controlled preview (2026)
Current priority: validation, readiness for institutional evaluation, evidence consolidation, security and reproducibility.
About the company →Evaluate whether NextGenAMR fits your organisation
We open conversations with laboratories, research and surveillance groups and institutions interested in a controlled, non-clinical evaluation. Tell us your context — we do not ask for patient data, samples, sequences or results.